Dr. Kumar Discusses Study of Ixazomib in Multiple Myeloma

Partner | Cancer Centers | <b>Mayo Clinic Cancer Center</b>

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses a study of ixazomib (Ninlaro) as maintenance therapy in multiple myeloma.

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, discusses a study of ixazomib (Ninlaro) as maintenance therapy in multiple myeloma.

The current analysis focuses on the long-term outcomes of patients treated with ixazomib in combination with standard doses of lenalidomide (Revlimid) and dexamethasone, initial results of which were published 2 years ago.

The study enrolled 42 patients out of the 66 who did not go to a stem cell transplant but continued therapy with ixazomib, with a median follow-up of 55 months.